El interés en corto de SOS da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de SOS. Los datos de interés en corto se actualizan cada dos semanas.

SOS (NYSE:SOS) Bolsa, Informe de interés en corto

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

SOS Limited American Depositary Shares, one hundred and fifty (150) Class A Ordinary Shares

SOS Ltd

OpenDAO

SosTravel.com SpA

Deoleo SA

STORAGE COMPUTER CORP by Storage Computer Corp.

Storage Computer Corp

SONAE SGPS SA MAIA REG SH by Sonae SGPS SA

Sonae SGPS SA

SOUTHERN STATES SIGN CO by Southern States Sign Co.

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/pressreleases/25/06/b45717442/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and-co-comme" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate.
Also Read: <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion</a>
BioNTech&#8217;s BNT327 is currently under extensive evaluation in multiple ongoing clinical trials, with over 1,000 patients having received the treatment to date. 
These evaluations include global Phase 3 trials with registrational potential, investigating BNT327 as a first-line treatment for both extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). 
Furthermore, BioNTech plans to initiate an additional global Phase 3 trial by the end of 2025 to assess the candidate&#8217;s efficacy in treating triple-negative breast cancer (TNBC).
Under the terms of the agreement, the companies will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. 
Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
Bristol Myers Squibb will pay BioNTech $1.5 billion in an upfront payment and $2 billion in non-contingent anniversary payments through 2028.
These tax-deductible charges will be recorded as Acquired IPR&amp;D Expense when incurred, with the $1.5 billion being incurred in Q2.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
BioNTech and Bristol Myers Squibb will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and Bristol-Myers Squibb.
In May, Bristol-Myers Squibb agreed to pay $350 million to the State of Hawaii to settle claims related to the prescription drug Plavix, an antiplatelet drug that prevents blood clots by keeping platelets in the blood from coming&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" rel="noreferrer noopener">together and making clots</a>.
The agreement resolves a lawsuit filed by the state that alleged the pharmaceutical company engaged in deceptive practices surrounding the development, labeling, and marketing of the drug.
Price Action: BNTX stock is trading higher by 14.8% to $109.95, and BMY stock is trading lower by 0.62% to $47.98 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asset-sales/25/06/45721138/dow-exits-dowaksa-jv-stays-course-on-best-owner-strategy" target="_blank" rel="noreferrer noopener">Dow Exits DowAksa JV, Stays Course On &#8216;Best-Owner&#8217; Strategy</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

News

Health Care

Movers

General

BNTX

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

U.S. stocks settled mixed on Friday, with the Dow Jones index gaining more than 50 points during the session after President Donald Trump accused China of "totally" breaching a tariff agreement, raising new fears over trade disputes.
Wall Street closed on a positive note last month, with the S&amp;P 500 gaining more than 6.2% in May and the Nasdaq jumping 9.6%. Both indices recorded their strongest months since November 2023. The Dow surged 3.9% for the month.
For the week, the S&amp;P 500 climbed, while the 30-stock Dow climbed 1.6%. The tech-laden Nasdaq, meanwhile, surged 2% last week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Leo Mariani
<ul class="wp-block-list">
<li>Analyst Firm: Roth Capital</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Maintained a Buy rating on Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) and cut the price target from $38 to $37 on May 27. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: On May 21, Sable Offshore announced a $200 proposed public offering.</li>
</ul>
Analyst: Richard Davis
<ul class="wp-block-list">
<li>Analyst Firm: Canaccord Genuity</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained a Hold rating on Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) and raised the price target from $100 to $115 on May 28. This analyst sees around 12% surge in the stock.</li>
<li>Recent News: On May 27, Okta reported first-quarter revenue of $688 million, beating analyst estimates of $680.25 million. The company reported adjusted earnings of 86 cents per share, beating analyst estimates of 77 cents per share.</li>
</ul>
Analyst: Trevor Walsh 
<ul class="wp-block-list">
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) and increased the price target from $240 to $310 on May 30. This analyst sees around 13% upside in the stock.</li>
<li>Recent News: On May 29, Zscaler reported third-quarter revenue of $678.03 million, beating the consensus estimate of $666.86 million.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Neutral rating on Cavco Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a price target of $550 on May 27. This analyst sees around 27% upside in the stock.</li>
<li>Recent News: On May 22, Cavco Industries posted upbeat quarterly results.</li>
</ul>
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained a Buy rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and boosted the price target from $205 to $210 on May 29. This analyst sees around 56% upside in the stock.</li>
<li>Recent News: On May 28, Nvidia reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 billion.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Price Target

Markets

Analyst Ratings

Trading Ideas

CVCO

NVDA

OKTA

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE
SINGAPORE, June 2, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or "HBNB") and JVSPAC Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) ("JVSPAC") announced today that the United States Securities and Exchange Commission ("SEC") has declared effective Hotel101's registration statement on Form F-4 filed with the SEC in connection with the previously announced business combination agreement between Hotel101 and JVSPAC.
JVSPAC has scheduled the Extraordinary General Meeting of Shareholders ("EGM") on June 24, 2025 to vote on the proposed business combination with Hotel101.
The business combination values Hotel101 at an equity value of US$2.3 billion. The closing of the business combination is expected to occur as soon as possible, subject to regulatory and shareholder approvals and other customary closing conditions. Upon listing, the combined company will operate as Hotel101 Global Holdings Corp. and trade under the ticker symbol "HBNB". Once listed, Hotel101 will become the first Filipino-owned company to be listed and traded on Nasdaq. Hotel101 is a subsidiary of Philippine-listed DoubleDragon Corporation (PSE: DD).

JVSA

U.S. SEC Declares Hotel101's Form F-4 Registration Effective As JVSPAC Sets June 24 Shareholder Meeting To Vote On Proposed Business Combination; Upon Listing, The Combined Co Will Operate As Hotel101 Global Holdings Corp. And Trade Under The Ticker Symbol "HBNB"

WIIM

Tempus AI shares are trading higher after the company introduced its fuses program for precision-based medicine and xM for advanced cancer treatment response monitoring.

Barclays analyst Andrew Mok maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $382 to $385.

Barclays Maintains Overweight on Cigna Group, Raises Price Target to $385

<a href="https://www.bloomberg.com/news/articles/2025-06-02/trump-wants-to-sell-us-s-1-million-barrel-reserve-of-diesel-fuel?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-02/trump-wants-to-sell-us-s-1-million-barrel-reserve-of-diesel-fuel?embedded-checkout=true</a>

'Trump Wants to Sell US's 1 Million Barrel Reserve of Diesel Fuel'- Bloomberg

Barclays analyst Adrienne Yih maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Equal-Weight and raises the price target from $327 to $485.

ULTA

Barclays Maintains Equal-Weight on Ulta Beauty, Raises Price Target to $485

BTIG analyst David Larsen upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Neutral to Buy and maintains the price target from $80 to $80.

Upgrades

DOCS

BTIG Upgrades Doximity to Buy, Maintains Price Target to $80

Barclays analyst David Strauss maintains Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) with a Equal-Weight and raises the price target from $250 to $280.

Barclays Maintains Equal-Weight on Heico, Raises Price Target to $280

Innventure's AeroFlexx Awarded U.S. Patents 11,548,709 And 12,071,292 For Sustainable Packaging Innovation

Barclays analyst Betty Jiang maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and raises the price target from $137 to $140.

Barclays Maintains Equal-Weight on EOG Resources, Raises Price Target to $140

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide
NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ --&nbsp;Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), a leading provider of high-quality, highly accurate long read sequencing platforms,&nbsp;to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439820-1&amp;h=3735549858&amp;u=https%3A%2F%2Fwww.targetals.org%2Fagri%2F&amp;a=ALS+Global+Research+Initiative+(AGRI)">ALS Global Research Initiative (AGRI)</a>, all data will be openly shared via the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439820-1&amp;h=2475819481&amp;u=https%3A%2F%2Fdataengine.targetals.org%2Fcollections&amp;a=Target+ALS+Data+Engine">Target ALS Data Engine</a>, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment.

PACB

Target ALS Partners With PacBio To Launch Largest Global Whole Genome Sequencing Initiative For ALS To Date

JP Morgan analyst Matthew Boss maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Overweight and raises the price target from $130 to $145.

JP Morgan Maintains Overweight on TJX Companies, Raises Price Target to $145

CSPI

CSP Inc. Added As Member Of Broad-Market Russell 3000 Index, Effective June 30, As Part Of 2025 Russell Indexes Reconstitution

Management

Ming Shing Group Holdings Announces Chi Ming Lam Resigned As Chairman And CEO; Appointed Wenjin Li As Chairman And CEO

Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-06-03. Here's what investors need to know before the announcement.
Analysts estimate that Sportsman's Warehouse will report an earnings per share (EPS) of $-0.47. 
Sportsman's Warehouse bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.10, leading to a 97.93% increase in the share price the following trading session.
Here's a look at Sportsman's Warehouse's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.02</td>
<td>-0.09</td>
<td>-0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.04</td>
<td>-0.14</td>
<td>-0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>98.0%</td>
<td>16.0%</td>
<td>7.000000000000001%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872977_0.png" alt="eps graph" />
<h3>Performance of Sportsman's Warehouse Shares</h3>
Shares of Sportsman's Warehouse were trading at $1.89 as of May 30. Over the last 52-week period, shares are down 50.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SPWH/earnings">To track all earnings releases for Sportsman's Warehouse visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SPWH

Sportsman's Warehouse's Earnings Outlook

Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-06-03. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Mama`s Creations will report an earnings per share (EPS) of $0.02.
Anticipation surrounds Mama`s Creations's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 0.29% drop in the share price the following trading session.
Here's a look at Mama`s Creations's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.04</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.01</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-15.0%</td>
<td>-0.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872967_0.png" alt="eps graph" />
<h3>Performance of Mama`s Creations Shares</h3>
Shares of Mama`s Creations were trading at $8.31 as of May 30. Over the last 52-week period, shares are up 24.44%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MAMA/earnings">To track all earnings releases for Mama`s Creations visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MAMA

Earnings Outlook For Mama's Creations

BTIG analyst Peter Saleh downgrades Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) from Buy to Neutral.

Downgrades

SHAK

BTIG Downgrades Shake Shack to Neutral

Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-06-03. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Yext will report an earnings per share (EPS) of $0.14.
Yext bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 4.12% drop in the share price on the subsequent day.
Here's a look at Yext's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.12</td>
<td>0.03</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.12</td>
<td>0.12</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-17.0%</td>
<td>13.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872956_0.png" alt="eps graph" />
<h3>Tracking Yext's Stock Performance</h3>
Shares of Yext were trading at $6.71 as of May 30. Over the last 52-week period, shares are up 36.76%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Yext</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Yext.
Analysts have given Yext a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $10.0, indicating a potential 49.03% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Exodus Movement, Weave Communications and Riskified, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Exodus Movement, with an average 1-year price target of $61.5, suggesting a potential 816.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for Weave Communications, with an average 1-year price target of $15.5, suggesting a potential 131.0% upside.</li>
<li>Analysts currently favor an Buy trajectory for Riskified, with an average 1-year price target of $6.25, suggesting a potential 6.86% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Exodus Movement, Weave Communications and Riskified are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yext</td>
<td>Buy</td>
<td>11.85%</td>
<td>$86.81M</td>
<td>-4.65%</td>
</tr>
<tr>
<td>Exodus Movement</td>
<td>Buy</td>
<td>23.87%</td>
<td>$21.10M</td>
<td>-5.16%</td>
</tr>
<tr>
<td>Weave Communications</td>
<td>Buy</td>
<td>18.31%</td>
<td>$39.95M</td>
<td>-13.02%</td>
</tr>
<tr>
<td>Riskified</td>
<td>Buy</td>
<td>7.83%</td>
<td>$40.45M</td>
<td>-3.74%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Yext ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, Yext is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Yext</h3>
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
<h3>Breaking Down Yext's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Yext's remarkable performance in 3 months is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 11.85%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Yext's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.43% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.65%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Yext's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.62, Yext adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/YEXT/earnings">To track all earnings releases for Yext visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YEXT

A Look at Yext's Upcoming Earnings Report

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-06-03. Here's what investors need to know before the announcement.
Analysts estimate that Guidewire Software will report an earnings per share (EPS) of $0.42. 
The market awaits Guidewire Software's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 7.35% drop in the share price on the following day.
Here's a look at Guidewire Software's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.30</td>
<td>0.54</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.51</td>
<td>0.43</td>
<td>0.62</td>
<td>0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-14.000000000000002%</td>
<td>12.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748872946_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Guidewire Software were trading at $215.02 as of May 30. Over the last 52-week period, shares are up 96.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Insights Shared by Analysts on Guidewire Software</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Guidewire Software.
The consensus rating for Guidewire Software is Outperform, based on 4 analyst ratings. With an average one-year price target of $235.75, there's a potential 9.64% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Docusign, Dynatrace and PTC, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Docusign, with an average 1-year price target of $96.07, suggesting a potential 55.32% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dynatrace, with an average 1-year price target of $59.44, suggesting a potential 72.36% downside.</li>
<li>Analysts currently favor an Outperform trajectory for PTC, with an average 1-year price target of $181.0, suggesting a potential 15.82% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Docusign, Dynatrace and PTC, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guidewire Software</td>
<td>Outperform</td>
<td>20.17%</td>
<td>$179.15M</td>
<td>-2.94%</td>
</tr>
<tr>
<td>Docusign</td>
<td>Neutral</td>
<td>8.97%</td>
<td>$616.04M</td>
<td>4.18%</td>
</tr>
<tr>
<td>Dynatrace</td>
<td>Buy</td>
<td>16.89%</td>
<td>$360.07M</td>
<td>1.52%</td>
</tr>
<tr>
<td>PTC</td>
<td>Outperform</td>
<td>5.52%</td>
<td>$530.10M</td>
<td>4.92%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Guidewire Software ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>Get to Know Guidewire Software Better</h3>
Guidewire Software provides software solutions for property and casualty insurers. Flagship product InsuranceSuite is an on-premises system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a cloud-based offering, as well as a variety of other add-on applications.
<h3>Breaking Down Guidewire Software's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Guidewire Software's remarkable performance in 3 months is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 20.17%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Guidewire Software's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Guidewire Software's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.94%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Guidewire Software's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.45%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Guidewire Software's debt-to-equity ratio surpasses industry norms, standing at 0.7. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/GWRE/earnings">To track all earnings releases for Guidewire Software visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

SOS

Interés en corto

SOS (NYSE:SOS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL